Toxicology – Adenosine

Core Concept

Adenosine is an extremely short-acting antiarrhythmic medication used primarily to terminate certain regular supraventricular tachycardias (SVTs) that depend on the AV node for maintenance.

Its extremely short duration of action makes both its therapeutic effects and most adverse effects brief.

In toxicology, adenosine may occasionally be useful for a true AV-node-dependent SVT, but it does not treat the underlying poisoning.

Main Clinical Role

Adenosine is most useful for:

• Regular, narrow-complex SVT
• AV nodal reentrant tachycardia (AVNRT)
• AV reentrant tachycardia (AVRT) involving an accessory pathway when the rhythm is appropriate for adenosine
• Selected regular monomorphic wide-complex tachycardias when SVT with aberrancy is being considered and use is clinically appropriate

Vagal maneuvers are generally attempted first in a stable patient with an appropriate regular SVT.

Mechanism of Action

Adenosine acts primarily at A1 adenosine receptors in cardiac nodal tissue.

This produces:

• Increased potassium conductance
• Reduced calcium-dependent activity
• Hyperpolarization of AV nodal cells
• Slowing of AV nodal conduction
• Increased AV nodal refractoriness

The key clinical result is:

Transient AV nodal block

If a tachycardia requires the AV node as part of its reentry circuit, briefly interrupting AV conduction can terminate the rhythm.

Why the Effect Is So Brief

Adenosine is rapidly taken up and metabolized by cells in blood and vascular tissues.

Its plasma half-life is only a few seconds.

Therefore:

• It must reach the circulation rapidly.
• Its therapeutic effect occurs almost immediately.
• Most adverse effects resolve rapidly.
• Recurrent tachycardia can occur if the underlying trigger persists.

Adenosine and Toxicologic Tachycardia

Adenosine should not be viewed as a general treatment for tachycardia caused by poisoning.

Many toxicologic tachycardias are compensatory or driven by persistent mechanisms such as:

• Sympathetic stimulation
• Hyperthermia
• Hypovolemia
• Hypoxia
• Metabolic acidosis
• Anticholinergic effects
• Withdrawal

In these situations, slowing the AV node does not correct the underlying problem.

The priority is to treat the toxicologic mechanism.

Theophylline Toxicity

Theophylline deserves special attention.

Theophylline is a methylxanthine and adenosine-receptor antagonist, so it can reduce the effectiveness of adenosine.

Theophylline poisoning commonly causes:

• Marked sinus tachycardia
• Supraventricular dysrhythmias
• Tremor
• Vomiting
• Hypokalemia
• Hyperglycemia
• Seizures

Therefore, persistent tachycardia in theophylline poisoning should not automatically be treated as an adenosine-responsive SVT.

Caffeine

Caffeine is also a methylxanthine and antagonizes adenosine receptors.

Recent substantial caffeine exposure may therefore reduce responsiveness to adenosine.

This interaction is especially relevant with large caffeine exposures or toxicity.

Dipyridamole

Dipyridamole can potentiate adenosine’s effects by interfering with cellular adenosine uptake.

This can produce a stronger or more prolonged response than expected.

Medication history is therefore important before administration.

Carbamazepine

Carbamazepine can enhance AV nodal conduction suppression and may increase the risk of excessive bradycardia or AV block when combined with adenosine.

Extra caution is appropriate when significant carbamazepine exposure is suspected.

What Adenosine Does NOT Usually Convert

Adenosine generally does not terminate rhythms whose circuit does not depend on the AV node.

Examples include:

• Atrial fibrillation
• Atrial flutter
• Most atrial tachycardias
• Sinus tachycardia
• Ventricular tachycardia

However, transient AV nodal blockade may sometimes expose underlying atrial activity and thereby help clarify the diagnosis.

Atrial Flutter

Adenosine may transiently block conduction through the AV node without eliminating the atrial flutter circuit.

The ECG may briefly reveal flutter waves more clearly.

Thus:

Adenosine may reveal atrial flutter without actually treating the underlying flutter.

Atrial Fibrillation

Adenosine does not terminate atrial fibrillation.

Particular caution is required when atrial fibrillation occurs with an accessory pathway, such as pre-excited atrial fibrillation, because AV nodal blockade can be dangerous.

An irregular wide-complex tachycardia should therefore not be reflexively treated with adenosine.

WPW and Accessory Pathways

The older source broadly lists Wolff-Parkinson-White syndrome as an indication, but this requires important clarification.

Adenosine can terminate orthodromic AVRT, in which the AV node forms part of the reentry circuit.

However:

Pre-excited atrial fibrillation is different and AV nodal blocking agents should be avoided.

Therefore, the rhythm itself—not simply the presence of WPW—determines whether adenosine is appropriate.

Regular vs Irregular Tachycardia

A high-yield distinction is:

Regular narrow-complex tachycardia

Adenosine may be appropriate if AV-node-dependent SVT is suspected.

Regular monomorphic wide-complex tachycardia

Adenosine may sometimes be considered in carefully selected stable cases.

Irregular wide-complex tachycardia

Do not routinely give adenosine; consider atrial fibrillation with pre-excitation, polymorphic VT, and other dangerous rhythms.

Unstable Tachycardia

Adenosine should not delay definitive treatment in a patient with hemodynamic instability.

Important instability findings include:

• Hypotension
• Shock
• Ischemic chest discomfort
• Acute heart failure
• Altered mental status from poor perfusion

An unstable tachyarrhythmia generally requires immediate synchronized cardioversion when appropriate, rather than repeated attempts at pharmacologic conversion.

Diagnostic Value

Because adenosine briefly suppresses AV nodal conduction, it can sometimes help distinguish:

• AV-node-dependent SVT
• Atrial flutter
• Certain atrial tachycardias

Continuous ECG recording during administration is useful because the diagnostic changes may last only seconds.

Expected Transient Effects

Patients should be warned, when circumstances allow, that adenosine can produce a sudden and unpleasant sensation.

Common transient symptoms include:

• Flushing
• Chest pressure or tightness
• Dyspnea
• Lightheadedness
• Nausea
• Sense of impending doom

These symptoms usually resolve rapidly because the drug disappears from the circulation within seconds.

Transient Bradycardia and AV Block

Adenosine intentionally produces transient AV nodal suppression.

The monitor may briefly show:

• Marked bradycardia
• AV block
• A short pause
• Transient asystole

This can look dramatic but usually resolves almost immediately.

Resuscitation equipment should nevertheless be readily available.

Bronchospasm

Adenosine can provoke bronchoconstriction.

Greater caution is warranted in patients with:

• Active bronchospasm
• Significant reactive airway disease
• Severe asthma

Clinically important bronchospasm is uncommon but potentially serious.

Major Contraindications / Situations Requiring Avoidance

Important situations include:

• Second-degree AV block without a functioning pacemaker
• Third-degree AV block without a functioning pacemaker
• Significant sinus-node dysfunction without pacing
• Irregular wide-complex tachycardia
• Pre-excited atrial fibrillation
• Significant active bronchospasm

Clinical context and ECG interpretation remain essential.

Administration Principle

Because adenosine disappears from circulation extremely rapidly, it must be delivered as a rapid IV bolus followed immediately by a flush.

A proximal peripheral IV can be used effectively; a central venous line is not routinely required.

This corrects the older source’s implication that adenosine needs to be administered through a central line.

Monitoring During Administration

Use:

• Continuous ECG monitoring
• Blood pressure monitoring
• Clinical observation
• Appropriate resuscitation equipment

A rhythm strip should ideally capture the period before, during, and after administration.

Pediatric Use

Adenosine is well established in modern pediatric resuscitation practice for appropriate SVT.

This differs from the older source’s statement that adequate pediatric evidence was lacking.

Pediatric administration is weight-based and should follow current pediatric resuscitation protocols.

Pregnancy

The old FDA pregnancy-letter categories such as Category C are obsolete.

Adenosine has an extremely short half-life and is used clinically during pregnancy when treatment of an appropriate SVT is necessary.

Pregnancy does not automatically preclude its use.

Failure of Adenosine

If an apparent SVT does not terminate, reconsider:

• Was the medication delivered rapidly enough?
• Is the rhythm actually AV-node dependent?
• Is this sinus tachycardia?
• Is it atrial flutter?
• Is it atrial tachycardia?
• Could this be ventricular tachycardia?
• Is a methylxanthine such as theophylline antagonizing adenosine?
• Is an ongoing toxicologic stimulus continuously recreating the rhythm?

Repeated treatment should not substitute for reassessing the ECG diagnosis.

Adenosine in Poisoning

In toxicology, always ask:

Is this a primary reentrant SVT, or is the tachycardia an expected physiologic consequence of the poison?

For example:

• Stimulant toxicity → control sympathetic excess and hyperthermia.
• Anticholinergic toxicity → treat the underlying syndrome.
• Theophylline toxicity → treat theophylline poisoning.
• Hypovolemia → restore appropriate circulating volume.
• Hypoxia → correct oxygenation/ventilation.
• Metabolic acidosis → identify and treat the cause.

Suppressing the heart rate without correcting the underlying process may provide little benefit and can sometimes be harmful.

Important Modernization of the Older Source

Several points require updating:

• Adenosine is not a general antidote for toxicologic tachycardia.
• Its principal role is AV-node-dependent reentrant SVT.
• A central IV line is not required; rapid administration through an appropriate peripheral line is standard.
• Pediatric use is now well established.
• FDA pregnancy letter categories are obsolete.
• WPW alone is not an indication; the specific rhythm determines whether adenosine is appropriate.
• Adenosine should be avoided in pre-excited atrial fibrillation.
• It does not normally convert atrial fibrillation or atrial flutter.
• Unstable tachyarrhythmias should receive appropriate immediate electrical management rather than allowing adenosine attempts to delay definitive treatment.

Key Points

• Adenosine is an ultra-short-acting AV nodal blocking antiarrhythmic.
• Its main therapeutic target is AV-node-dependent reentrant SVT, particularly AVNRT and appropriate AVRT.
• Its half-life is only a few seconds.
• It transiently slows or blocks AV nodal conduction.
• It does not treat ordinary sinus tachycardia caused by poisoning.
• Atrial flutter and atrial fibrillation generally do not convert with adenosine.
• Adenosine can sometimes transiently reveal atrial activity and aid rhythm diagnosis.
• Theophylline and caffeine antagonize adenosine.
• Dipyridamole potentiates adenosine.
• Use caution with significant conduction disease and bronchospastic disease.
• Avoid routine adenosine in an irregular wide-complex rhythm, particularly possible pre-excited atrial fibrillation.
• WPW-associated orthodromic AVRT may respond, but pre-excited AF is a fundamentally different situation.
• Administration requires a rapid IV bolus followed immediately by a flush.
• A central line is not routinely necessary.
• Brief flushing, chest discomfort, dyspnea, and a sensation of impending doom are common but usually disappear within seconds.
• Continuous ECG monitoring and resuscitation capability should be available.
• In poisoning, always treat the underlying toxicologic mechanism rather than treating the heart rate alone.